Medical device giant Medtronic (NYSE:MDT) landed CE Mark approval in the European Union for its Sentrino minimally invasive continuous glucose monitoring system, the 1st device of its kind designed to improve glucose control for critical care patients.
The Sentrino CGM System continuously displays the patient’s interstitial glucose value and show real-time trend data to help the patients with glucose control. When the glucose values fall outside the target range, the system provides predictive alarms and alerts, according to a press release.
"Despite its many benefits, good glycemic control is difficult to achieve in the CCU, and that’s why we developed Sentrino. Medtronic has a decade of CGM expertise, and we coupled it with extensive clinical research to develop the Sentrino CGM System for critically ill patients," VP & general manager Greg Meehan said in prepared remarks. "Given the market need for CGM in CCU patients, we believe the market potential will exceed $1 billion globally."
The Sentrino CGM System integrates clinical work-flow in the hospital to improve the quality and efficiency of maintaining glucose control for critical care patients, and allows clinicians to use event-based clinical protocol instead of current time-based measurement protocol, the standard of care in which blood glucose measurements are taken every 2 to 4 hours, Medtronic noted.
Sentrino currently is under investigation and is not available for sale in the U.S.
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.